MMRd/MSI-H Stage II-III Endometrial Cancer
1 clinical trials · Condition
◉ Watch MMRd/MSI-H Stage II-III Endometrial Cancer
| Record | Firm | Date |
|---|---|---|
| Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer (NCT07013851) | Grupo Español de Investigación en Cáncer de Ovario | 2025-10-01 |
Track MMRd/MSI-H Stage II-III Endometrial Cancer automatically
Every clearance here is in the API, with alerts when new ones post.